{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:32:18Z","timestamp":1792794738224,"version":"4.5.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Breakthrough Level 2"},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Breast Cancer Research","award":["BC180476\/BC180476P1"],"award-info":[{"award-number":["BC180476\/BC180476P1"]}],"id":[{"id":"https:\/\/ror.org\/03xzf6x18","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA271915"],"award-info":[{"award-number":["CA271915"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DoD Breast Cancer Research Program","award":["BC210945"],"award-info":[{"award-number":["BC210945"]}],"id":[{"id":"https:\/\/ror.org\/03xzf6x18","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100032616","name":"Starr Cancer Consortium","doi-asserted-by":"crossref","award":["I16-0064"],"award-info":[{"award-number":["I16-0064"]}],"id":[{"id":"10.13039\/100032616","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Transformative Breast Cancer Consortium","id":[{"id":"https:\/\/ror.org\/009tqys91","id-type":"ROR","asserted-by":"crossref"}]},{"name":"DoD Breast Cancer Research Program","award":["W81XWH2120034"],"award-info":[{"award-number":["W81XWH2120034"]}],"id":[{"id":"https:\/\/ror.org\/03xzf6x18","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA274291"],"award-info":[{"award-number":["CA274291"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZP-6177"],"award-info":[{"award-number":["ZP-6177"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mantle Cell Lymphoma Research Initiative"},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Functional Genomics Initiative"},{"name":"Clinical Trials Innovation"},{"name":"Sandra and Edward Meyer Cancer Center"},{"name":"Department of Radiation Oncology"},{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Luke Heller TECPR2 Foundation"},{"name":"Lytix Biopharma","id":[{"id":"https:\/\/ror.org\/016ftvg65","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Noxopharm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hormone receptor\u2013positive (HR+) breast cancer responds poorly to immune checkpoint inhibitors (ICIs). In some settings, radiation therapy (RT) has been shown to mediate immunostimulatory effects and promote ICI sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated whether hypofractionated RT may be successfully combined with ICIs in a mouse model of multifocal, metachronous HR+ mammary carcinogenesis. We hypothesized that focal RT targeting the first detectable (primary) tumor combined with ICIs may generate effective immunity, delaying the development of new lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Focal RT in various doses and fractionations limited primary tumor growth, with an optimum for a 20-Gy \u00d7 2 regimen (ablative in approximately 90% of mice). The degree of primary disease control, however, did not necessarily correlate with overall survival extension because of changes in the development of new neoplastic lesions contributing to global tumor burden. Adding a PD-1 blocker to focal RT delivered in a 10-Gy \u00d7 3, 20-Gy \u00d7 2, or 8-Gy \u00d7 6 regimen failed to alter overall survival extension enabled by RT alone. Similar results were obtained with a CTLA4 blocker, an IL-1\u03b2 inhibitor, and a PD-1 blocker plus recombinant FLT3LG when combined with the 10-Gy \u00d7 3 regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this model of HR+ mammary carcinogenesis, RT to the primary tumor ameliorates overall survival (to an extent based on dose and fractionation). Increasing local control through RT alone or RT plus immunotherapy beyond a hitherto undefined threshold, however, does not necessarily inhibit the development of subsequent nonirradiated neoplasms and hence does not necessarily provide extra overall survival benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djae329","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T07:41:59Z","timestamp":1733816519000},"page":"934-947","source":"Crossref","is-referenced-by-count":10,"title":["Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor\u2013positive mammary carcinogenesis"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-8778","authenticated-orcid":false,"given":"Aitziber","family":"Buqu\u00e9","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]},{"name":"Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center , Philadephia, PA 19111,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5758-9424","authenticated-orcid":false,"given":"Norma","family":"Bloy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0558-5322","authenticated-orcid":false,"given":"Giulia","family":"Petroni","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]},{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence 50134,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jim\u00e9nez-Cortegana","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-2596","authenticated-orcid":false,"given":"Ai","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]},{"name":"Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center , Philadephia, PA 19111,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2930-8573","authenticated-orcid":false,"given":"Cristina","family":"Iribarren","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7420-4394","authenticated-orcid":false,"given":"Takahiro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Galassi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8767-0722","authenticated-orcid":false,"given":"Michal","family":"Hensler","sequence":"additional","affiliation":[{"name":"Sotio , Prague 170 00, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-8761","authenticated-orcid":false,"given":"Bhavneet","family":"Bhinder","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]},{"name":"Caryl and Israel Englander Institute for Precision Medicine , New York, NY 10065,","place":["United States"]},{"name":"Institute for Computational Biomedicine, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-131X","authenticated-orcid":false,"given":"Andrea","family":"Guarracino","sequence":"additional","affiliation":[{"name":"Department of Genetics, Genomics, and Informatics, University of Tennessee Health Science Center , Memphis, TN 38163,","place":["United States"]},{"name":"Human Technopole , Milan 20157,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-8330","authenticated-orcid":false,"given":"Brady","family":"Rippon","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7977-8020","authenticated-orcid":false,"given":"Manuel","family":"Beltran-Visiedo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]},{"name":"Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center , Philadephia, PA 19111,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-389X","authenticated-orcid":false,"given":"Ruth","family":"Soler-Agesta","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]},{"name":"Department of Biochemistry and Molecular and Cell Biology, University of Zaragoza\/Arag\u00f3n Health Research Institute , Zaragoza 50009,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Pannellini","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-479X","authenticated-orcid":false,"given":"Jitka","family":"Fucikova","sequence":"additional","affiliation":[{"name":"Sotio , Prague 170 00, Czech Republic"},{"name":"Department of Immunology, Charles University, 2nd Faculty of Medicine, and University Hospital Motol , Prague 150 06, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4426-0499","authenticated-orcid":false,"given":"Sandra","family":"Demaria","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]},{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-439X","authenticated-orcid":false,"given":"Xi Kathy","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-9617","authenticated-orcid":false,"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[{"name":"Caryl and Israel Englander Institute for Precision Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8227-8924","authenticated-orcid":false,"given":"Silvia C","family":"Formenti","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]},{"name":"Sandra and Edward Meyer Cancer Center , New York, NY 10065,","place":["United States"]},{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-8500","authenticated-orcid":false,"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine , New York, NY 10065,","place":["United States"]},{"name":"Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center , Philadephia, PA 19111,","place":["United States"]},{"name":"Caryl and Israel Englander Institute for Precision Medicine , New York, NY 10065,","place":["United States"]},{"name":"Sandra and Edward Meyer Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"2025121020015885400_djae329-B1","first-page":"524","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025121020015885400_djae329-B2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41571-018-0089-9","article-title":"Progress in adjuvant systemic therapy for breast cancer","volume":"16","author":"Ponde","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121020015885400_djae329-B3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMc1715968","article-title":"Breast-Cancer Recurrence after Stopping Endocrine Therapy","volume":"378","author":"Pan","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121020015885400_djae329-B4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2025121020015885400_djae329-B5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","article-title":"Immunomodulation by targeted anticancer agents","volume":"39","author":"Petroni","year":"2021","journal-title":"Cancer Cell"},{"key":"2025121020015885400_djae329-B6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41573-022-00415-5","article-title":"Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment","volume":"21","author":"Petroni","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025121020015885400_djae329-B7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41577-020-0300-y","article-title":"Immunomodulation by anticancer cell cycle inhibitors","volume":"20","author":"Petroni","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025121020015885400_djae329-B8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121020015885400_djae329-B9","first-page":"187","article-title":"Immunosurveillance in clinical cancer management","volume":"74","author":"Kroemer","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025121020015885400_djae329-B10","doi-asserted-by":"crossref","first-page":"S1260","DOI":"10.1016\/j.annonc.2023.10.011","article-title":"LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+\/HER2\u2013 breast cancer","volume":"34","author":"Cardoso","year":"2023","journal-title":"Annals of Oncology"},{"key":"2025121020015885400_djae329-B11","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025121020015885400_djae329-B12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025121020015885400_djae329-B13","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"2025121020015885400_djae329-B14","first-page":"e351","article-title":"Geographic density of linear accelerators and receipt of radiation therapy for prostate cancer","volume":"111","author":"Bates","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121020015885400_djae329-B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025121020015885400_djae329-B16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121020015885400_djae329-B17","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"2025121020015885400_djae329-B18","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1158\/1078-0432.CCR-06-0593","article-title":"The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas","volume":"12","author":"Newcomb","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025121020015885400_djae329-B19","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J Clin Invest"},{"key":"2025121020015885400_djae329-B20","doi-asserted-by":"crossref","first-page":"e28133","DOI":"10.4161\/onci.28133","article-title":"Is tumor (R)ejection by the immune system the \"5th R\" of radiobiology?","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"2025121020015885400_djae329-B21","doi-asserted-by":"crossref","first-page":"2057892","DOI":"10.1080\/2162402X.2022.2057892","article-title":"Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice","volume":"11","author":"Zhou","year":"2022","journal-title":"Oncoimmunology"},{"key":"2025121020015885400_djae329-B22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2025121020015885400_djae329-B23","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/s41590-020-0751-0","article-title":"Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy","volume":"21","author":"Yamazaki","year":"2020","journal-title":"Nat Immunol"},{"key":"2025121020015885400_djae329-B24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41419-023-05829-6","article-title":"Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia","volume":"14","author":"Sugita","year":"2023","journal-title":"Cell Death Dis"},{"key":"2025121020015885400_djae329-B25","doi-asserted-by":"crossref","first-page":"2222560","DOI":"10.1080\/2162402X.2023.2222560","article-title":"Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference","volume":"12","author":"Gregucci","year":"2023","journal-title":"Oncoimmunology"},{"key":"2025121020015885400_djae329-B26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41571-021-00579-w","article-title":"Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer","volume":"19","author":"Petroni","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121020015885400_djae329-B27","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025121020015885400_djae329-B28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002485","article-title":"Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Leidner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025121020015885400_djae329-B29","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1038\/s41467-020-17644-0","article-title":"Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer","volume":"11","author":"Buque","year":"2020","journal-title":"Nat Commun"},{"key":"2025121020015885400_djae329-B30","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-20-3871","article-title":"Radiotherapy delivered before CDK4\/6 inhibitors mediates superior therapeutic effects in ER(+) breast cancer","volume":"27","author":"Petroni","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025121020015885400_djae329-B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.mcb.2020.08.003","article-title":"MPA\/DMBA-driven mammary carcinomas","volume":"163","author":"Buque","year":"2021","journal-title":"Methods Cell Biol"},{"key":"2025121020015885400_djae329-B32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0360-3016(85)90366-9","article-title":"A review of alpha\/beta ratios for experimental tumors: Implications for clinical studies of altered fractionation","volume":"11","author":"Williams","year":"1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121020015885400_djae329-B33","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"2025121020015885400_djae329-B34","first-page":"100141","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"2025121020015885400_djae329-B35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"2025121020015885400_djae329-B36","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"2025121020015885400_djae329-B37","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1158\/1538-7445.AM2021-2701","article-title":"Abstract 2701: molecular profiling to assess the immune response to neoadjuvant SABR in early breast cancer","volume":"81","author":"Spears","year":"2021","journal-title":"Cancer Res"},{"key":"2025121020015885400_djae329-B38","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","article-title":"CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"key":"2025121020015885400_djae329-B39","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"2025121020015885400_djae329-B40","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res"},{"key":"2025121020015885400_djae329-B41","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1084\/jem.184.5.1953","article-title":"Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified","volume":"184","author":"Maraskovsky","year":"1996","journal-title":"J Exp Med"},{"key":"2025121020015885400_djae329-B42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nm0697-625","article-title":"Flt3 ligand induces tumor regression and antitumor immune responses in vivo","volume":"3","author":"Lynch","year":"1997","journal-title":"Nat Med"},{"key":"2025121020015885400_djae329-B43","doi-asserted-by":"crossref","first-page":"e25771","DOI":"10.4161\/onci.25771","article-title":"Trial watch: Dendritic cell-based interventions for cancer therapy","volume":"2","author":"Vacchelli","year":"2013","journal-title":"Oncoimmunology"},{"key":"2025121020015885400_djae329-B44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"2025121020015885400_djae329-B45","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-23-3206","article-title":"Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites","volume":"30","author":"Hou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025121020015885400_djae329-B46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/2326-6066.CIR-21-1105","article-title":"Myeloid-derived suppressor cells and radiotherapy","volume":"10","author":"Jimenez-Cortegana","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025121020015885400_djae329-B47","doi-asserted-by":"crossref","first-page":"xiii","DOI":"10.1016\/S1937-6448(23)00048-5","article-title":"Myeloid-derived suppressor cells: emerging players in cancer and beyond","volume":"375","author":"Jimenez-Cortegana","year":"2023","journal-title":"Int Rev Cell Mol Biol"},{"key":"2025121020015885400_djae329-B48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djae329\/61051484\/djae329.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/5\/934\/61051484\/djae329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/5\/934\/61051484\/djae329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T01:02:11Z","timestamp":1765414931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/5\/934\/7921421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,11]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djae329","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,11]]}}}